stockrowPTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.
- Revenue
- +69.6%
- EPS
- −409.7%
- Free cash flow
- +90.3%
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
Follow PTCT
Alert me
PTC Therapeutics, Inc. (PTCT) Shares outstanding
PTC Therapeutics, Inc.'s shares outstanding at the end of fiscal 2025 was $88.3M, up 14.9% from $76.8M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $83.5M. Over the past ten years it has ranged from $33.6M (fiscal 2015) to $88.3M (fiscal 2025) — the current reading is the highest in ten years. PTC Therapeutics, Inc. ranks 182nd of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $88.3M | 14.92% |
| FY2024 | $76.8M | 2.68% |
| FY2023 | $74.8M | 4.34% |
| FY2022 | $71.7M | 1.79% |
| FY2021 | $70.5M | 6.72% |
| FY2020 | $66.0M | 12.17% |
| FY2019 | $58.9M | 26.38% |
| FY2018 | $46.6M | 18.87% |
| FY2017 | $39.2M | 15.09% |
| FY2016 | $34.0M | 1.24% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $83.5M | (9.28%) |
| Jun 2026 | $92.0M | 11.51% |
| Mar 2026 | $82.5M | (6.56%) |
| Dec 2025 | $88.3M | 1.37% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IMVT Immunovant, Inc. compare | $205.5M |
| COGT Cogent Biosciences, Inc. compare | $171.0M |
| SRRK Scholar Rock Holding Corporation compare | $130.6M |
| CGON CG Oncology, Inc. compare | $88.2M |
| PTCT PTC Therapeutics, Inc. | $83.5M |
| MIRM Mirum Pharmaceuticals, Inc. compare | $66.1M |
| KOD Kodiak Sciences Inc. compare | $62.6M |
| MANE Veradermics Incorporated compare | $40.4M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | $40.2M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on PTCT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement